Why does the current biomedical research system primarily favour Caucasian individuals?

This week I am joined by Casper Barnes, the founder and CEO of AminoChain. He's actively working on rectifying this inequality through the creation of a blockchain-based platform that enables donors to monitor their samples and earn a share of the proceeds when they are utilised for commercial purposes. This will help to incentivise participation in research from a wider range of people, and ensure that donors are fairly compensated for their contributions.

Connect with us: Neuroute - copilot for clinical trials https://www.neuroute.co/

Twitter: https://twitter.com/livialifes

LinkedIn: